In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

The biotech recently revealed promising data from trials of its oral weight loss candidate. Since then ... seeing them in the ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

Analyzing H&H's Q3 results and investment strategy in the healthcare industry, highlighting undervaluation and raising the ...

A simple online search for semaglutide, the active ingredient in Ozempic or Wegovy, can lead consumers down a rabbit hole of seemingly reputable online pharmacies in search of weight loss drugs ... to ...

A Novo Nordisk trial also discovered an association between Wegovy prescriptions and fewer hospitalizations for any cause. In the study, 33.4% of patients taking Wegovy were admitted, compared to ...

Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the ...

Novo Nordisk, the maker of Ozempic ... of major cardiovascular events in adults with type 2 diabetes and known heart disease.